Dariohealth Corp. quarterly report, Q1 FY2014

Business Context and Reporting Period

LabStyle Innovations Corp. (the registrant named in this filing; identified in the request as Dariohealth Corp.) filed this unaudited Form 10-Q for the quarter ended March 31, 2014. The company was a development-stage mobile-health business developing Dario, a smartphone-connected diabetes monitoring and management solution. It reported no commercial revenue through the quarter.

Financial Results and Position

Unless otherwise stated, amounts are U.S. dollars in thousands. The filing does not report meaningful revenue margins because there was no revenue.

At March 31, 2014, cash and cash equivalents were $3,812; total current assets were $4,620 and current liabilities were $1,217. Total assets were $5,727. The balance sheet reported a $5,775 warrant liability and stockholders’ deficiency of $1,265. No conventional borrowing or debt balance is identified in the filing. The company raised net financing cash of $4,002 in the quarter, including $3,813 from a private placement and $189 from option and warrant exercises; investing cash outflow was $116.

Material Changes and Unusual Items

• Net loss decreased year over year, primarily alongside lower general and administrative and warrant-related financial expense. Research and development and marketing/pre-production costs increased as the company expanded product development and prepared for launch.
• Operating cash use increased from $972 to $2,337 despite the lower net loss.
• In February 2014, the company raised approximately $3,813 net through a private placement issuing 2,226,956 common shares and warrants. Warrant terms include anti-dilution provisions and potential additional adjustment shares; the warrants are accounted for as liabilities and remeasured at fair value. The warrant liability was $5,775 at quarter-end.
• Common shares outstanding rose from 20,071,816 at December 31, 2013 to 22,879,368 at March 31, 2014; 22,966,389 were reported outstanding as of May 14, 2014.

Outlook, Risks, and Contingencies

The company began a soft launch of Dario in selected jurisdictions in March 2014, with initial distributor shipments in late March. It held CE Mark certification and reported filing a U.S. FDA 510(k) application, with a response expected later in 2014. Management planned to expand the soft launch, ramp production, marketing and distribution, continue product development, and pursue regulatory approvals and patent protection. After the quarter, the company reported Italian reimbursement coverage and a U.S. patent notice of allowance.

Management estimated available liquidity would support planned activity into October 2014, including anticipated initial sales. Cost reductions might extend operations by up to three months, but were not assured. The filing states that additional capital will be required and that financing or adequate sales may not be available; these conditions raise substantial doubt about the company’s ability to continue as a going concern. Actual cash needs could exceed estimates. The filing reported no legal proceedings or off-balance-sheet arrangements.

Important Facts for Investors to Verify

• Whether Dario sales and distributor shipments developed sufficiently to generate meaningful revenue and whether the product launch could scale.
• The status and timing of FDA clearance and other regulatory approvals, as well as reimbursement and distribution arrangements.
• Cash burn, actual runway, funding requirements, and the availability and terms of any additional financing.
• Potential dilution and liability volatility from warrants, anti-dilution protections, adjustment-share provisions, and outstanding equity awards.
• The assumptions behind management’s liquidity outlook and the going-concern uncertainty.